In children with type I SMA or presymptomatic infants with an <i>SMN1</i> deletion, three <i>SMN2</i> copies was associated with later symptom onset, slower decline in motor function and longer survival compared with two <i>SMN2</i> copies. This evidence concerns the gene SMN2 and spinal muscular atrophy, type 1.